lifestyle.thedishh.com

Author: ALX Oncology

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 27, 2026
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

February 19, 2026
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

February 19, 2026
ALX Oncology Announces Pricing of Underwritten Offering

January 30, 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

January 30, 2026